December 17th, 2014
Immunovia will introduce its blood based test for early detection of pancreatic cancer firstly in the US

Immunovia, a company located in Lund, Sweden, will introduce a blood test for early detection of pancreatic cancer. The company created by investigators at Create Health Cancer Center in Lund, has developed an antibody array technology platform that is using the immune system as an early, specific and sensitive sensor for the disease. The test is a microchip with a panel of clinically relevant antibodies which is called a biomarker signature. The signature binds with extremely high specificity and sensitivity in a specific pattern the proteins that are present in the blood sample and are associated with the disease. The test can give a clear answer about the presence or absence of the disease in early stages.

The first test in the pipeline is the early diagnosis of pancreatic cancer and the reason Immunovia has chosen pancreatic cancer is very obvious. There is currently no standard diagnostic tool or established early detection method for pancreatic cancer. When diagnosed early, surgical resection offers the best chance for long-term control of pancreatic cancer, yet most patients are diagnosed at later stages and are not eligible for surgery. The 5 year survival rate is 3-5 % making pancreatic cancer the 4th deadly cancer. Tests sensitive enough to detect pancreatic cancer in its earliest stages are therefore urgently needed.

Immunovia´s test is designed to answer this urgent need of early diagnosis of pancreatic cancer and will be introduced for screening programs of high risks groups.

The first reference sites for early detection of pancreatic cancer with retrospective studies are planned in the US in 2015 and 2016 but other partnerships in Scandinavia and the rest of Europe are also defined and will be implemented shortly.

As the platform can be applied for other diseases, such as autoimmune conditions, Immunovia has SLE diagnosis in its pipeline. Research studies have also been performed for breast cancer and prostate cancer.

Immunovia is privately owned by its founders and also industry investors.

The company and its technology comes from Professor Carl Borrebaeck and his research team at Create Health Cancer Center. Professor Carl Borrebaeck is the founder and the Chairman of the Board.

Summary of the article from Life Science Sweden magazine: (in Swedish)